Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris

NCT02322866 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT02322866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02322866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Lead sponsor
Almirall, S.A.
Phase
Phase 3
Overall status
Completed
Start date
December 3, 2014
Completion date
January 12, 2017
Enrollment
1,034 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris